Wednesday 20 June 2018

Amgen drug cuts cancer bone problem risk

A third pivotal trial of Amgen's denosumab found that it delayed by 21 per cent the risk of fractures and other bone complications in men with advanced prostate cancer compared with current therapy. Amgen filed last month for US Food and D


Amgen osteoporosis drug wins approval

The US Food and Drug Administration has approved the sale of Amgen's osteoporosis drug Prolia to help prevent fractures in post-menopausal women. The approval comes just days after the medicine received European approval.  &n


Amgen plans expansion at DuBiotech

Dubai Biotechnology and Research Park (DuBiotech), a life sciences hub, said Amgen International, a top biotechnology company, discussed expansion plans during a meeting of senior management members. Discussing Amgen’s future plans at the

 1 2 3 4 5 >  Last ›

calendarCalendar of Events